HBW Advisory Services LLC Has $2.96 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

HBW Advisory Services LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,484 shares of the medical research company's stock after acquiring an additional 925 shares during the quarter. HBW Advisory Services LLC's holdings in Amgen were worth $2,955,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Ascent Wealth Partners LLC raised its position in shares of Amgen by 0.7% in the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after buying an additional 64 shares during the period. ICICI Prudential Asset Management Co Ltd increased its stake in Amgen by 242.2% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock worth $6,255,000 after acquiring an additional 16,985 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Amgen by 285.4% in the fourth quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company's stock valued at $102,820,000 after buying an additional 292,137 shares during the period. Aire Advisors LLC lifted its holdings in shares of Amgen by 26.3% during the 4th quarter. Aire Advisors LLC now owns 13,280 shares of the medical research company's stock valued at $3,461,000 after acquiring an additional 2,762 shares in the last quarter. Finally, Beacon Harbor Wealth Advisors Inc. purchased a new position in Amgen in the 4th quarter worth approximately $3,531,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Bank of America raised their target price on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler reduced their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $309.22.

Amgen Stock Up 0.0%

Shares of Amgen stock traded up $0.09 during midday trading on Thursday, reaching $287.10. 2,517,436 shares of the company's stock traded hands, compared to its average volume of 2,805,485. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company's 50 day simple moving average is $282.39 and its 200 day simple moving average is $285.31. The company has a market cap of $154.38 billion, a price-to-earnings ratio of 38.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.96 earnings per share. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.